By Ben Glickman


Cabaletta Bio announced it had received orphan drug designation from regulators for its potential treatment for an inflammatory muscle condition.

The company said Thursday that the Food and Drug Administration had granted the designation to CABA-201 in the treatment of idiopathic inflammatory myopathies, also called myositis.

Myositis is a category of autoimmune diseases characterized by inflammation and muscle weakness.

Cabaletta said CABA-201 is in development for a potential treatment of autoimmune diseases driven by B cells.

Orphan drug status is given by the FDA to drugs or biologics meant to treat rare diseases.


Write to Ben Glickman at ben.glickman@wsj.com


(END) Dow Jones Newswires

02-01-24 1659ET